McGill launches study to examine if an antidepressant slows the progression of COVID-19 Mental health care and the virtual visitAs an increasing number of Canadians suffer from mental illness, FPs are being called on to help even more. Sexual dysfunction may persist after discontinuing SSRI or SNRI antidepressants Health Canada safety review reports on risk of persistent, worsening or new sexual dysfunction after stopping SSRI or SNRI treatment. Study: Link established between loneliness and depressive symptoms Usual doses of tramadol may cause visual and auditory hallucinations Health Canada safety review identifies new risk, particularly in people older than age 65. New prescription hypnotic for insomnia now available in Canada First marketed orexin receptor antagonist is approved for adults with difficulties in falling asleep and/or maintaining sleep. Managing people with opioid-use disorder in the emergency department Canadian Association of Emergency Physicians offers recommendations for emergency healthcare providers to help address Canada’s opioid crisis. Nonbenzodiazepine hypnotic, Lunesta (eszopiclone) now marketed in Canada Approved for short-term use in adults with difficulty falling asleep, or nocturnal or early morning awakenings. Rx Q&A: Trintellix for improved function in patients with major depressive disorder Provide families with guidance on how to reset sleep times disrupted by COVID-19 Pandemic has significantly altered normal sleep patterns for children and teenagers First Previous 18 19 20 21 22 Next Last